Key Highlights

  • Silence Therapeutics (NASDAQ:SLN) posted 95.21% over the month to rank third among 1,259 small caps, with a 219.14% gain year to date.
  • Lyell Immunopharma (NASDAQ:LYEL) gained 72.23% over the month and 42.95% in the latest week, yet it remains 49.79% lower year to date.
  • Teladoc Health (NYSE:TDOC) climbed 60.31% in the month, with third-quarter adjusted EBITDA of USD 79.4 million behind it. Jin Medical International (NASDAQ:ZJYL) rose 55.87% after a USD 159.4 million acquisition.
  • Capricor Therapeutics (NASDAQ:CAPR) rose 31.93% in the week, with the monthly figure not visible, ahead of a November 22, 2026 FDA decision date for deramiocel.

Silence Therapeutics (NASDAQ:SLN): Phase 2 Data Lifts a Month-Long Climb Without a Separate Trigger

Silence Therapeutics (NASDAQ:SLN) climbed 95.21% over the month to USD 19.76, ranking third among 1,259 small caps screened, and no single catalyst for the month was identified. Simple arithmetic places the price near USD 10.12 a month earlier. The central fundamental development was the August 10, 2026 Phase 2 SANRECO readout, in which divesiran in polycythemia vera produced an 88% clinical response against 19% for placebo. Randomized results in a rare blood disease can lift approval prospects and partnering interest, and momentum buyers may have joined in. The shares are up 219.14% year to date and 188.39% over six months. Cash of USD 72.1 million at June 30, 2026 sits against a six-month net loss of USD 27.2 million, and a Phase 3 start planned for the first half of 2027 keeps an Equity raise on the table as a risk. Thin trading among small caps can reverse a move of this size.

Lyell Immunopharma (NASDAQ:LYEL): Results, a Placement and Trial Data Meet a Deep Drawdown

Lyell Immunopharma (NASDAQ:LYEL) is up 72.23% over the month and 42.95% over the past week, closing at USD 15.73. The week included the November 4, 2026 third quarter report and an USD 80.0 million private placement, which management says funds operations into 2028, alongside cash of USD 194.0 million. The company release cites PiNACLE data for ronde-cel in 44 efficacy-evaluable patients, with a 91% overall response rate and a 77% complete response rate, although the price move cannot be attributed to any single headline. Data, funding and a low base often re-rate small biotechs. Even so, the six-month change is negative 21.10% and the year-to-date change negative 49.79%, so the rally sits inside a deep drawdown. A market Capitalization near USD 382.28 million is roughly twice cash by simple arithmetic, while the net loss widened to USD 45.5 million. Dilution, binary pivotal data expected in mid-2027 and thin Volume are the risks, and the move may reverse.

Teladoc Health (NYSE:TDOC): Shrinking Revenue With Narrower Losses Draws Buyers Back

Teladoc Health (NYSE:TDOC) is up 60.31% over the month to USD 9.33, with 17.80% of that gain arriving in the past week. The clearest dated event is the third quarter report on October 28, 2026. Revenue of USD 605.1 million fell 3%, while adjusted EBITDA rose 14% to USD 79.4 million and the net loss narrowed to USD 26.9 million. Published coverage reported a jump of 11.5% that day. Markets often pay more for a shrinking Top Line when losses narrow and cash generation improves, and short covering or rotation into beaten-down sector peers may have contributed, though neither was confirmed as a driver. On roughly 179 million shares, the calculated Market Value is near USD 1.7 billion. Six-month and year-to-date gains are 35.02% and 33.29%. BetterHelp is guided to a decline of 16.1% to 12.9% for the year, the main operating risk, while full-year loss per share is guided between USD 0.95 and USD 0.75. Wide spreads and a Reversal remain possible.

Jin Medical International (NASDAQ:ZJYL): Closed Acquisition Brings Dilution and a Sharp Move

Jin Medical International (NASDAQ:ZJYL) is up 55.87% over the month and 59.95% over the week to USD 3.06, though it is still 28.85% lower year to date. No single catalyst for the weekly move was identified beyond the acquisition already filed, so the explanation is general context. The company closed its USD 159.4 million acquisition of Huaxia Qiying on September 24, 2026, issuing roughly 79.8 million shares in total. Small Nasdaq companies often re-rate when a deal changes the story or when a tiny float meets sudden volume. With about 158 million shares, the calculated market value is near USD 483 million, against roughly USD 15.19 million cited in August 2026, which means holders were diluted. Revenue was USD 8.9 million for the six months to March 31, 2026, while the six-month gain stands at 44.59%. Thin trading means a few trades can move the price, and the move may reverse.

Capricor Therapeutics (NASDAQ:CAPR): An FDA Date Makes the Weekly Gain a Binary Regulatory Event

Capricor Therapeutics (NASDAQ:CAPR) rose 31.93% over the week to USD 8.23, and its one-month figure was not visible in the data reviewed. No catalyst for the week was confirmed. The regulatory mechanism is the core: the FDA extended its decision date for deramiocel to November 22, 2026, from August 22, 2026, after a major amendment that included 24-month open-label extension data. From USD 5.88 on July 12, 2026, the price is about 40.0% higher (calculated). With USD 0 of revenue and a net loss of USD 129.4 million, the valuation rests on the outcome, and the calculated value of about USD 538 million at USD 8.23 reflects that. A rejection, a delay or a dilutive offering could reverse the move, the latest session fell 7.71%, and a small number of trades can move the price.

Where Things Stand

Each name rests on a different event, which is why the group looks mixed. Silence Therapeutics (NASDAQ:SLN) reflects Phase 2 data and a path toward Phase 3. Lyell Immunopharma (NASDAQ:LYEL) reflects results, a placement and trial data. Teladoc Health (NYSE:TDOC) reflects a quarter with narrower losses. Jin Medical International (NASDAQ:ZJYL) reflects a closed deal. Capricor Therapeutics (NASDAQ:CAPR) is shown on its weekly move, with its FDA date still ahead. These lists cover small caps of 300 million to 2 billion USD and mid caps of 2 billion to 10 billion USD, drawn from a screener snapshot dated November 5, 2026. Small cap rallies can reverse because trading is thin and news can change the setup quickly.